证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司 2023 年第二次临时股东大会会议资料 二〇二三年十月 1 | 2023 | 年第二次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2023 | 年第二次临时股东大会会议议程 | 6 | | 2023 | 年第二次临时股东大会会议议案 | 8 | | 议案一 | 关于使用部分超募资金投资建设新项目的议案 | 8 | 迈得医疗工业设备股份有限公司 2023年第二次临时股东大会会议资料 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，出席 大会的股东或其代理人须在会议召开前 30 分钟到会议现场办理签到手续，并请 按股东大会登记方法等有关规定出示股东账户卡（如有）、身份证明文件或法人 单位证明、授权委托书等。在会议主持人宣布现场出席会议的股东和代理人人数 及所持有表决权的股份总数之前，会议登记应当终止。现场参会登记终止后出席 的股东或其代理人，不得参加现场表决，但可以列席会议。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等权 利 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2023-029 二、监事会会议审议情况 会议经与会监事审议并书面表决通过了如下议案： （一）审议通过了《关于使用部分超募资金投资建设新项目的议案》 公司监事会认为：公司本次使用部分超募资金投资建设新项目审议程序符合 《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》等法律、法规、规范性文件以及《迈得医疗工业设备 股份有限公司募集资金管理制度》的规定，符合公司主营业务发展方向，有利于 提高募集资金的使用效率，不存在变相改变募集资金投向的情形，不存在损害股 东利益的情况。 综上，公司监事会同意公司使用部分超募资金投资建设新项目。 迈得医疗工业设备股份有限公司 第四届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第四届监事会第十二次 会议（以下简称" ...

证券代码：688310 证券简称：迈得医疗 公告编号：2023-030 迈得医疗工业设备股份有限公司 关于使用部分超募资金投资建设新项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 迈得医疗工业设备股份有限公司（以下简称"公司"或"迈得医疗"） 于 2023 年 10 月 9 日召开了第四届董事会第十三次会议、第四届监事会第十二次 会议，分别审议通过了《关于使用部分超募资金投资建设新项目的议案》，同意 公司使用超募资金总计人民币 6,421.29 万元用于投资建设新项目。公司独立董事 对上述事项发表了同意的独立意见，广发证券股份有限公司（以下简称"保荐机 构"）对上述事项出具了无异议的核查意见，上述事项需提交公司股东大会审议。 投资项目名称：年产 35 台药械组合类智能装备扩建项目。 投资金额及资金来源：预计项目总投资 6,421.29 万元，拟使用超募资金 金额 6,421.29 万元，将根据项目建设进度投入（最终投资金额以项目建设实际投 入为准）。 本次投资不构成关联交易，不构成重大资产重组。 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2023-028 迈得医疗工业设备股份有限公司 第四届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 迈得医疗工业设备股份有限公司（以下简称"公司"）第四届董事会第十三 次会议（以下简称"本次会议"）于 2023 年 10 月 9 日以现场加通讯的方式在公 司会议室召开。本次会议的通知已于 2023 年 9 月 28 日以电子邮件方式送达全体 董事。本次会议由董事长林军华先生召集并主持，应出席会议董事 7 人，实际出 席会议董事 7 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、 行政法规以及《迈得医疗工业设备股份有限公司章程》的相关规定。 二、董事会会议审议情况 具体内容详见公司于同日披露在上海证券交易所网站（www.sse.com.cn）的 《迈得医疗工业设备股份有限公司关于使用部分超募资金投资建设新项目的公 告》（公告编号：2023-030）。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2023-031 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第二次临时股东大会 召开日期时间：2023 年 10 月 30 日 14 点 00 分 召开地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设备股份有限公司 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 迈得医疗工业设备股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 网络投票起止时间：自 2023 年 10 月 30 日 至 2023 年 10 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2023年10月30日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2023-027 迈得医疗工业设备股份有限公司 三、 参加人员 董事长、总经理：林军华先生 董事会秘书：林栋先生 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日 发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年 半年度经营成果、财务状况，公司计划于 2023 年 9 月 21 日上午 10:00-11:00 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2023 年 9 月 21 日(星期四) 上午 10:00-11:00 会议召 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 15%[14]. - The company's operating revenue for the first half of 2023 was approximately ¥197.66 million, representing a 48.37% increase compared to ¥133.22 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥39.87 million, a significant increase of 277.13% from ¥10.57 million in the previous year[21]. - The basic and diluted earnings per share for the first half of 2023 were both ¥0.34, reflecting a 277.78% increase compared to ¥0.09 in the same period last year[21]. - The net cash flow from operating activities increased by 490.78% to approximately ¥94.90 million, up from ¥16.06 million in the previous year[21]. - The total assets of the company at the end of the reporting period were approximately ¥1.17 billion, an increase of 12.38% from ¥1.04 billion at the end of the previous year[21]. - The company's gross profit margin improved to 45%, up from 42% in the previous year, reflecting better cost management and pricing strategies[14]. - The company achieved a revenue of 197.66 million yuan in the reporting period, representing a year-on-year growth of 48.37%[122]. - The net profit attributable to shareholders reached 39.87 million yuan, a significant increase of 277.13% compared to the previous year[122]. - Total assets increased to 1.1668 billion yuan, up by 12.38% year-on-year[122]. Market Expansion and Strategy - The company expects a revenue growth forecast of 10-15% for the second half of 2023, driven by new product launches and market expansion strategies[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[14]. - A strategic acquisition of a local medical device company is in progress, expected to enhance product offerings and distribution channels[14]. - The company is actively exploring high-value medical consumables in niche markets, focusing on the combination of drugs and devices[122]. - The company has established long-term partnerships with well-known medical consumable manufacturers, including Weigao (01066.HK) and Kangdelai (603987.SH)[118]. Research and Development - Investment in R&D increased by 25% compared to the same period last year, focusing on innovative medical equipment technologies[14]. - The company's R&D expenditure as a percentage of operating revenue decreased to 7.24%, down 6.74 percentage points from 13.98% in the previous year[21]. - The company has developed multiple products that have overcome key technical challenges, achieving domestic firsts and replacing imports, thus filling domestic gaps[29]. - The company has filed multiple patents, including 17 invention patents and 8 utility model patents, demonstrating its commitment to innovation in medical technology[79]. - The company has established a comprehensive R&D system across eight modules, including materials science, mechanics, and software[99]. - The company has a total of 592 intellectual property applications, with 422 granted, indicating a strong focus on innovation[83]. Product Development and Innovation - The company has launched two new high-value medical consumables, projected to contribute an additional RMB 100 million in revenue by year-end[14]. - The company introduced new equipment such as glass pre-filled syringe cleaning and siliconization packaging machines, enhancing production capacity and market competitiveness[22]. - New products developed during the reporting period include automatic welding machines for reagent storage and automatic assembly machines for nutrition delivery tubes, expanding the product line[50]. - The company has developed advanced technologies for high-speed multi-material feeding and soft catheter shaping, enhancing production efficiency and product quality[78]. - The company has developed a new infusion device packaging equipment that reduces the main line length by 2 meters, addressing space constraints[82]. Operational Efficiency and Automation - The intelligent manufacturing equipment primarily automates the assembly of medical consumables, indicating a shift towards automation in the medical supply industry[36]. - The average production efficiency in smart factories has improved by 34.8%, showcasing the effectiveness of intelligent manufacturing solutions[39]. - The company has achieved full automation in the production of dialysis devices, greatly reducing the risk of contamination and adverse reactions in patients[79]. - The company has implemented a new automatic feeding technology that reduced the material jamming probability from 0.05% to less than 0.01%[106]. - The company has introduced automated assembly technology for blood dialysis devices, minimizing contamination risks and improving production consistency[108]. Risk Management - The company has identified potential risks related to supply chain disruptions and is actively developing contingency plans to mitigate these risks[14]. - The company is exposed to risks related to international relations, trade sanctions, and currency fluctuations that could impact its overseas business operations[135]. - The company faced a risk of declining gross margin due to rising labor costs and increased competition[130]. Environmental and Social Responsibility - The company invested 10.62 million CNY in environmental protection during the reporting period[161]. - The company has implemented measures to ensure that wastewater and emissions meet relevant standards, including compliance with the IV class standard for surface water[163]. - The company received the "Green Factory" honor from Taizhou City in 2021, reflecting its commitment to environmental protection and sustainable practices[164]. - The company promotes energy-saving and low-carbon practices, encouraging employees to adopt green office methods and providing charging facilities for electric vehicles[165]. Shareholder and Corporate Governance - The company has established a three-year dividend return plan for shareholders from 2022 to 2024[195]. - The company has committed to not engaging in any competitive activities against its main business, ensuring protection of shareholder interests[191]. - The company has confirmed that there are no unfulfilled commitments that would require further explanation[169]. - The company has maintained compliance with all commitments related to shareholding and management during the reporting period[171].

证券代码：688310 证券简称：迈得医疗 公告编号：2023-016 迈得医疗工业设备股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 5 月 10 日(星期三) 至 5 月 17 日(星期三)16:00 前通过公 司邮箱（zq@maiderchina.com）进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日 披露公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 5 月 26 日下午 13:00-14:30 举行 2022 年度暨 2023 年第一季度业绩说明会，就 投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度及 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥72,708,646.44, representing a year-on-year increase of 39.83%[5] - The net profit attributable to shareholders for Q1 2023 was ¥13,411,992.23, showing a significant increase of 457.73% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,384,381.02, reflecting a year-on-year growth of 661.69%[5] - Basic earnings per share for Q1 2023 were ¥0.16, up 433.33% from the previous year[6] - Net profit for Q1 2023 was ¥15,623,627.82, significantly higher than ¥2,205,325.56 in Q1 2022, marking a 608.5% increase[20] - Earnings per share for Q1 2023 were ¥0.16, compared to ¥0.03 in Q1 2022, indicating a substantial growth in profitability[21] - The company reported a significant increase in other income, which rose to ¥7,289,577.72 in Q1 2023 from ¥2,998,548.72 in Q1 2022, a growth of 143.5%[19] Cash Flow - The net cash flow from operating activities reached ¥42,615,106.97, marking an increase of 275.36% year-on-year[6] - Cash inflow from operating activities in Q1 2023 totaled ¥144,638,732.58, compared to ¥37,736,410.50 in Q1 2022, representing a 284.5% increase[21] - Cash outflow from operating activities for Q1 2023 was ¥102,023,625.61, up from ¥62,038,188.52 in Q1 2022, reflecting a 64.5% increase[21] - Net cash flow from operating activities was $42,615,106.97, a decrease of $24,301,778.02 compared to the previous period[22] - Net cash flow from investing activities was -$54,165,252.47, compared to -$11,227,276.47 in the previous period[22] - Cash and cash equivalents at the end of the period totaled $209,923,467.15, down from $278,858,739.67 in the previous period[22] - The company reported a net decrease in cash and cash equivalents of $11,928,400.16, compared to a decrease of $35,982,912.71 in the previous period[22] - The cash inflow from investment activities was $70,195,000.00, while cash outflow was $81,422,276.47[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,087,370,320.57, an increase of 4.73% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 1,087,370,320.57, an increase from CNY 1,038,260,721.13 as of December 31, 2022, reflecting a growth of approximately 4.0%[15] - The total current assets increased to CNY 678,446,600.29 from CNY 635,880,464.58, representing a growth of about 6.3%[16] - The cash and cash equivalents decreased slightly to CNY 217,751,592.74 from CNY 224,946,034.81, a decline of approximately 3.0%[15] - The accounts receivable rose to CNY 122,233,542.63 from CNY 121,053,391.62, indicating a marginal increase of about 1.0%[16] - The inventory increased significantly to CNY 150,655,144.93 from CNY 116,579,561.59, marking an increase of approximately 28.2%[16] - The total non-current assets amounted to CNY 408,923,720.28, up from CNY 402,380,256.55, showing a growth of about 1.3%[16] - The total liabilities increased to CNY 1,087,370,320.57, reflecting a rise from the previous period, indicating a potential increase in leverage[16] - The company reported a significant increase in contract liabilities to CNY 76,102,851.10 from CNY 60,047,730.38, which is an increase of approximately 26.7%[16] - The company's total liabilities as of Q1 2023 amounted to ¥240,000,349.11, compared to ¥208,658,267.53 in Q1 2022, an increase of 15.0%[18] - Total equity for Q1 2023 was ¥847,369,971.46, up from ¥829,602,453.60 in Q1 2022, indicating a growth of 2.1%[18] Research and Development - Research and development expenses totaled ¥7,517,084.03, which is a decrease of 14.08% year-on-year, accounting for 10.34% of operating revenue[6] - Research and development expenses for Q1 2023 were ¥7,517,084.03, slightly down from ¥8,748,981.09 in Q1 2022, a decrease of 14.1%[19] Shareholder Information - The company reported a total of 3,300 common shareholders at the end of the reporting period[10] - The top shareholder, Lin Junhua, holds 39,986,000 shares, representing 47.66% of the total shares[11] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[14] - There are no significant changes in shareholder relationships or financing activities reported during this period[13] - The company did not apply new accounting standards for the first quarter of 2023[23]

Financial Performance - The company has not yet achieved profitability since its listing [4]. - In 2022, the company's operating revenue reached ¥383,489,867.44, representing a 21.54% increase compared to ¥315,525,810.78 in 2021 [21]. - The net profit attributable to shareholders was ¥67,026,580.60 in 2022, a growth of 3.95% from ¥64,479,103.03 in 2021 [23]. - The company's total assets increased by 18.08% to ¥1,038,260,721.13 at the end of 2022, up from ¥879,311,660.19 in 2021 [21]. - The basic earnings per share for 2022 was ¥0.80, a 3.90% increase from ¥0.77 in 2021 [22]. - The cash flow from operating activities for 2022 was ¥97,339,070.00, which is a 14.67% increase from ¥84,886,101.10 in 2021 [21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥57,603,685.34 in 2022, showing a slight decrease of 0.69% compared to the previous year [21]. - The company reported a total revenue of 5,564 million RMB for the year, with a net profit of 1,994.75 million RMB, reflecting a growth of approximately 6% compared to the previous year [103]. Corporate Governance - The company has a clear governance structure with all board members present at the meeting [5]. - The company has not disclosed any special arrangements for corporate governance [7]. - The company has not violated decision-making procedures for external guarantees [7]. - The company plans to continue protecting minority shareholder rights and improving investor relations in compliance with relevant laws and regulations [186]. - The company held two shareholder meetings in 2022, approving a total of 16 proposals, ensuring compliance with legal and regulatory requirements [191]. - The board of directors convened eight meetings in 2022, passing 37 resolutions, to ensure effective governance and decision-making [192]. - The supervisory board held eight meetings in 2022, approving 27 proposals, to oversee the company's operations and compliance [192]. Research and Development - The company submitted 82 new patent applications during the reporting period, including 37 invention patents [33]. - A total of 77 patents were granted, with 2 being invention patents, and the cumulative number of granted patents reached 315 [33]. - The total R&D expenditure for the year was ¥36,662,050.97, a decrease of 4.67% compared to the previous year [96]. - R&D expenditure accounted for 9.56% of total revenue, down by 2.63 percentage points from 12.19% in the previous year [96]. - The company has established a comprehensive R&D system across eight major modules, emphasizing interdisciplinary collaboration [108]. - The company has received recognition as a national-level specialized and innovative "little giant" enterprise [91]. - The company has ongoing research and development efforts to further enhance its core technologies and expand its market presence [86]. Market Expansion and Strategy - The company plans to explore high-value medical consumables in niche markets and expand its overseas presence to enhance profitability [180]. - The company aims to expand its market presence in Europe, the Americas, and developing countries to increase market penetration and share [184]. - The company is actively pursuing market expansion and innovation in product development to meet customer needs [92]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $15 million allocated for potential deals [200]. - The company is focused on expanding its market presence through innovative product development and strategic enhancements in manufacturing processes [116]. Risks and Challenges - The company has detailed potential risks and countermeasures in its annual report, emphasizing the importance of investor caution [4]. - The company faces risks related to the rapid technological updates in the medical consumables sector, which may impact its competitive edge if it fails to innovate [126]. - The company is exposed to risks of key technology infringement, which could adversely affect its profitability [129]. - The company has a potential risk of seasonal fluctuations in operating performance, with lower sales typically in the first half of the year [130]. - The company benefits from a 15% corporate income tax rate due to its status as a high-tech enterprise, but changes in tax policies could significantly impact its financial performance [134]. Product Development and Innovation - The company has developed multiple products that have overcome key technical challenges, achieving domestic firsts and replacing imports, thus filling domestic gaps [36]. - The company has launched several intelligent control system software versions for medical equipment, including V1.0 for automatic packaging and assembly machines [40]. - The company has developed a comprehensive range of automated equipment for medical consumables, including blood collection needle assembly machines, insulin syringe assembly machines, and various production lines for dialysis and infusion devices [58]. - The company has developed new products including automatic production lines for high-pressure contrast agents and fully automated packaging lines for HPV testing, expanding its product range [59]. - The company has successfully launched automated assembly products, including infusion devices and catheter series equipment, enhancing its market offerings [113]. Financial Health and Investments - The company has invested a total of $90 million in the development of a high universality plate chain conveyor platform, achieving a cumulative investment of $80.33 million, with the project currently in the trial production phase [99]. - A total investment of $180 million has been allocated for the automatic assembly process of insulin pens, with a cumulative investment of $141.58 million, also in the trial production phase [99]. - The company reported a gross margin of 40%, reflecting improved operational efficiency [200]. - The company achieved operating revenue of 383,489,867.44 CNY, representing a year-on-year growth of 21.54% [138]. - The company’s gross profit margin increased from 50.12% in 2021 to 50.46% in 2022, despite potential future pressures from rising labor costs and increased competition [130]. Talent and Human Resources - The company emphasizes talent development and cultural construction to enhance its operational capabilities and employee engagement [34]. - The number of R&D personnel increased to 109, accounting for 18.23% of the total workforce, compared to 19.18% in the previous year [106]. - The total compensation for R&D personnel reached 1,610.73 million RMB, with an average salary of 14.91 million RMB, up from 14.20 million RMB last year [106]. - The company is actively engaging in talent retention strategies by offering stock incentives to key personnel [199]. - The management team has shown a commitment to aligning their interests with shareholders through stock ownership [199].